Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1755791

Cover Image

PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1755791

Radiotheranostics Market Growth, Size, Trends Analysis - By Radioisotope, By Approach, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

PUBLISHED:
PAGES: 222 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4250
PDF (Group License)
USD 5650
PDF (Company License)
USD 7450

Add to Cart

Radiotheranostics Market Introduction and Overview

According to SPER market research, 'Global Radiotheranostics Market Size- By Radioisotope, By Approach, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Radiotheranostics Market is predicted to reach 35.22 billion by 2034 with a CAGR of 13.74%.

Radiotheranostics is a new area in medicine that merges diagnosis and treatment using radiopharmaceuticals. It uses radiotracers, which are molecules with radioactive isotopes, to diagnose and treat diseases at the same time. Techniques like positron emission tomography (PET) or single-photon emission computed tomography (SPECT) are used to identify specific targets in the body, offering precise and personalized diagnosis by detailing the disease's location and extent. The treatment entails providing radiation therapy to the illness site.

Restraints: The high cost of radiopharmaceuticals and radiotheranostics treatments can cause problems for patients and healthcare professionals alike. The cost-effectiveness and affordability of these technologies need to be addressed in order to ensure further adoption and market expansion.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Radioisotope, By Approach, By Application

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc. (Lantheus), Telix Pharmaceuticals Limited, ITM Radiopharma, Life Molecular Imaging, RadioMedix, IsoTherapeutics Group, LLC, Q BioMed Inc, Nordic Nanovector ASA.

Global Radiotheranostics Market Segmentation:

By Radioisotope: Based on the Radioisotope, Global Radiotheranostics Market is segmented as; Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90.

By Approach: Based on the Approach, Global Radiotheranostics Market is segmented as; Targeted Therapeutic, Targeted Diagnostic.

By Application: Based on the Application, Global Radiotheranostics Market is segmented as; Oncology, Non-oncology.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25127

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Radiotheranostics Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Radiotheranostics Market

7. Global Radiotheranostics Market, By Radioisotope (USD Million) 2021-2034

  • 7.1. Iodine-131
  • 7.2. Iodine-123
  • 7.3. Gallium-68
  • 7.4. Lutetium-177
  • 7.5. 18F with Y-90
  • 7.6. Others

8. Global Radiotheranostics Market, By Approach (USD Million) 2021-2034

  • 8.1. Targeted Therapeutic
  • 8.2. Targeted Diagnostic

9. Global Radiotheranostics Market, By Application (USD Million) 2021-2034

  • 9.1. Oncology
    • 9.1.1. Thyroid Cancer
    • 9.1.2. Neuroendocrine Tumor
    • 9.1.3. Hepatocellular Carcinoma
    • 9.1.4. Prostate Cancer
    • 9.1.5. Others
  • 9.2. Non-oncology
    • 9.2.1. Neurological Disorders
    • 9.2.2. Arthritis
    • 9.2.3. Others

10. Global Radiotheranostics Market, (USD Million) 2021-2034

  • 10.1. Global Radiotheranostics Market Size and Market Share

11. Global Radiotheranostics Market, By Region, (USD Million) 2021-2034

  • 11.1. Asia-Pacific
    • 11.1.1. Australia
    • 11.1.2. China
    • 11.1.3. India
    • 11.1.4. Japan
    • 11.1.5. South Korea
    • 11.1.6. Rest of Asia-Pacific
  • 11.2. Europe
    • 11.2.1. France
    • 11.2.2. Germany
    • 11.2.3. Italy
    • 11.2.4. Spain
    • 11.2.5. United Kingdom
    • 11.2.6. Rest of Europe
  • 11.3. Middle East and Africa
    • 11.3.1. Kingdom of Saudi Arabia
    • 11.3.2. United Arab Emirates
    • 11.3.3. Qatar
    • 11.3.4. South Africa
    • 11.3.5. Egypt
    • 11.3.6. Morocco
    • 11.3.7. Nigeria
    • 11.3.8. Rest of Middle-East and Africa
  • 11.4. North America
    • 11.4.1. Canada
    • 11.4.2. Mexico
    • 11.4.3. United States
  • 11.5. Latin America
    • 11.5.1. Argentina
    • 11.5.2. Brazil
    • 11.5.3. Rest of Latin America

12. Company Profile

  • 12.1. Novartis AG
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2. Bayer AG
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3. Progenics Pharmaceuticals, Inc.(Lantheus)
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4. Telix Pharmaceuticals Limited
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5. ITM Radiopharma
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6. Life Molecular Imaging
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7. RadioMedix
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8. IsoTherapeutics Group, LLC
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9. Q BioMed Inc
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10. Nordic Nanovector ASA
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments
  • 12.11. Others

13. Conclusion

14. List of Abbreviations

15. Reference Links

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!